

B₁

In a preferred embodiment, the adjuvant is described in EP 735898B1.

IN THE CLAIMS:

Please cancel claims 93-112 without prejudice to subsequent revival.

Please add new claims 113-144 as follows.

B₂

113. (new) A method for eliciting or enhancing an immune response to HER-2/neu protein, the method comprising the step of administering to a warm-blooded animal a composition comprising an isolated protein comprising a Her2/Neu ECD-PD fusion protein in an amount effective to elicit or enhance the immune response, the Her-2/neu ECD-PD fusion protein comprising a Her-2/neu extracellular domain fused to a Her-2/neu phosphorylation domain, wherein the fusion protein is encoded by a nucleic acid that hybridizes under stringent conditions to the complement of a nucleic acid sequence encoding an amino acid sequence of SEQ ID NO:6, wherein the hybridization reaction is incubated in a solution comprising 5x SSC at a temperature of 50-65°C and washed in a solution comprising 0.2x SSC and 0.1% SDS at a temperature of 65°C, and wherein the protein is capable of producing an immune response in a warm-blooded animal.

114. (new) The method of claim 113, wherein the composition is administered in the form of a vaccine.

115. (new) The method of claim 113, wherein the fusion protein comprises an amino acid sequence of SEQ ID NO:6.

116. (new) The method of claim 113, wherein the fusion protein comprises an amino acid sequence of SEQ ID NO:7.

117. (new) The method of claim 113, wherein the fusion protein is lipidated.

118. (new) The method of claim 113, wherein the composition comprises a physiologically acceptable carrier or diluent.

119. (new) The method of claim 118, wherein the composition comprises an oil-in-water emulsion.

120. (new) The method of claim 119, wherein the composition comprises tocopherol.

B₂
121. (new) The method of claim 113, wherein the composition comprises an immunostimulatory substance.

122. (new) The method of claim 121, wherein the composition comprises an immunostimulatory substance comprising 3D-MPL, QS21, or a combination of 3D-MPL and QS21.

123. (new) The method of claim 121, wherein the composition comprises an immunostimulatory substance comprising 3dMPL and QS21 in an oil-in-water emulsion.

124. (new) The method of claim 123, wherein the composition comprises tocopherol.

125. (new) The method of claim 113, wherein the composition comprises a CpG-containing oligonucleotide.

126. (new) The method of claim 113, wherein the step of administering comprises transfecting cells of the warm-blooded animal *ex vivo* with the composition comprising the fusion protein and subsequently delivering the transfected cells to the warm-blooded animal.

B₂
127. (new) A method for eliciting or enhancing an immune response to HER-2/neu protein, the method comprising the step of administering to a warm-blooded animal a composition comprising a nucleic acid molecule encoding a HER-2/neu fusion protein in an amount effective to elicit or enhance the immune response, the HER-2/neu fusion protein comprising a HER-2/neu extracellular domain fused to a HER-2/neu phosphorylation domain, wherein the nucleic acid hybridizes under stringent conditions to the complement of a nucleic acid sequence encoding the amino acid sequence of SEQ ID NO:6, wherein the hybridization reaction is incubated in a solution comprising 5x SSC at a temperature of 50-65°C and washed in a solution comprising 0.2x SSC and 0.1% SDS at a temperature of 65°C, and wherein the protein is capable of producing an immune response in a warm-blooded animal.

128. (new) The method of claim 127, wherein the nucleic acid molecule is in the form of a vaccine.

129. (new) The method of claim 127, wherein the step of administering comprises transfecting cells of the warm-blooded animal *ex vivo* with the composition comprising the nucleic acid molecule and subsequently delivering the transfected cells to the warm-blooded animal.

130. (new) The method of claim 127, wherein the composition comprises a lipid.

131. (new) The method of claim 127, wherein the composition comprises a physiologically acceptable carrier or diluent.

132. (new) The method of claim 127, wherein the nucleic acid molecule is a viral vector encoding a HER-2/neu fusion protein.

133. (new) The method of claim 127, wherein the viral vector is an adenoviral vector.

B₂
134. (new) The method of claim 129, wherein the nucleic acid molecule is a viral vector encoding a HER-2/neu fusion protein.

135. (new) The method of claim 134, wherein the viral vector is an adenoviral vector.

136. (new) The method of claim 127, wherein the nucleic acid molecule encodes a protein comprising an amino acid sequence of SEQ ID NO:6.

137. (new) The method of claim 127, wherein the nucleic acid molecule encodes a protein comprising an amino acid sequence of SEQ ID NO:7.

138. (new) A method for eliciting or enhancing an immune response to HER-2/neu protein, the method comprising the step of administering to a warm-blooded animal a composition comprising a viral vector comprising a nucleic acid molecule encoding a HER-2/neu fusion protein in an amount effective to elicit or enhance the immune response, the HER-2/neu fusion protein comprising a HER-2/neu extracellular domain fused to a HER-2/neu phosphorylation domain, wherein the nucleic acid hybridizes under stringent conditions to the complement of a nucleic acid sequence encoding the amino acid sequence of SEQ ID NO:6, wherein the hybridization reaction is